Bristol-Myers Squibb (BMS) has signed a clinical collaboration agreement to investigate the combination of its Opdivo (nivolumab) with Clovis Oncology’s Rubraca in a Phase II and two Phase III clinical trials to treat various types of tumours.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor, while Rubraca is an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes such as PARP-1, PARP-2 and PARP-3.

Set to be initiated by the end of this year, the multi-arm clinical trials will be initially performed in the US and Europe, with plans to extend to other countries.

Bristol-Myers Squibb oncology development head Fouad Namouni said: “This clinical collaboration addresses areas of unmet medical need where the combination of Opdivo and Rubraca may lead to an additional treatment option for patients with difficult to treat cancers.

“We are committed to investigating a wide range of oncology therapies and look forward to studying the combination of Clovis’ PARP inhibitor and our immunotherapy.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

A Phase III trial will assess Opdivo and Rubraca as monotherapies, as well as a combination therapy in newly diagnosed subjects with stage III/IV high-grade ovarian, fallopian tube or primary peritoneal cancer.

"We are committed to investigating a wide range of oncology therapies and look forward to studying the combination of Clovis’ PARP inhibitor and our immunotherapy."

Another Phase III trial will evaluate the same in stage IV or recurrent locally advanced inoperable triple-negative breast cancer (TNBC) patients with a homologous recombination deficiency (HRD).

The ovarian cancer trial will include placebo, while the TNBC trial will compare the drug candidates’ effects with chemotherapy.

Additionally, the safety and efficacy of the combination will be investigated in a Phase II trial in metastatic castration-resistant prostate cancer (mCRPC) patients.

BMS will fund and perform the breast and prostate cancer trials, while Clovis will sponsor and conduct the ovarian cancer trial.

Image: Micrograph of a mucinous ovarian tumour. Photo: courtesy of Nephron.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact